Here is the design of a clinical trial:

Official Title: Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19

Included conditions:
- Covid19
- Coronavirus Infection
- SARS-CoV Infection

Study Armgroups:
- {'label': 'Ivermectin', 'type': 'ACTIVE_COMPARATOR', 'description': 'Participants on this arm will receive orally one (1) daily dose of ivermectin 300 mcg/kg for three (3) consecutive days, starting at the enrolment visit.', 'interventionNames': ['Drug: Ivermectin']}
- {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Participants on this arm will receive orally one (1) daily dose of placebo for three (3) consecutive days, starting at the enrolment visit.', 'interventionNames': ['Drug: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'Ivermectin', 'description': 'One daily dose of NOXAL-Ivermectin Oral Solution (6 mg/mL) at 300mcg/kg for three (3) consecutive days. A weight-equivalence table will be used to determine each participant´s dose (number of oral drops/day).', 'armGroupLabels': ['Ivermectin'], 'otherNames': ['Noxal']}
- {'type': 'DRUG', 'name': 'Placebo', 'description': 'The placebo presentation will be an oral drop solution undistinguishable from ivermectin, but without this device pharmaceutical ingredient.', 'armGroupLabels': ['Placebo']}

Primary Outcomes:
- {'measure': 'Proportion of patients with a positive SARS-CoV-2 PCR.', 'description': 'Proportion of patients with a positive SARS-CoV-2 PCR from a nasopharyngeal swab at day 7 post-treatment', 'timeFrame': '7 days post-treatment'}

Please estimate the sample size based on the assumption: 
Not provided
Numbers to be randomized (sample size)
          The planned sample size is 186 SARS-CoV-2 PCR positive patients: 93 patients to treatment and 93 to the placebo group.